Chapter 7 132 55. Khalil R, Lalai RA, Wiweger MI, Avramut CM, Koster AJ, Spaink HP, et al. Glomerular permeability is not affected by heparan sulfate glycosaminoglycan deficiency in zebrafish embryos. American journal of physiology Renal physiology. 2019;317(5):F1211-F6. 56. Roberts IS, Gleadle JM. Familial nephropathy and multiple exostoses with exostosin-1 (EXT1) gene mutation. Journal of the American Society of Nephrology : JASN. 2008;19(3):450-3. 57. Colvin RB, Chang A. Diagnostic Pathology: Kidney Diseases: Elsevier Health Sciences; 2015. 58. Wuyts W, Van Hul W. Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes. Human mutation. 2000;15(3):220-7. 59. Bovee JV. Multiple osteochondromas. Orphanet journal of rare diseases. 2008;3:3. 60. Bovee JV, Hogendoorn PC. Multiple osteochondromas. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumours : pathology and genetics tumours of soft tissue and bone. Lyon: IARC Publications; 2002. p. 360–2. 61. Le Merrer M, Legeai-Mallet L, Jeannin PM, Horsthemke B, Schinzel A, Plauchu H, et al. A gene for hereditary multiple exostoses maps to chromosome 19p. Human molecular genetics. 1994;3(5):717-22. 62. Hameetman L, Bovee JV, Taminiau AH, Kroon HM, Hogendoorn PC. Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management. Hereditary cancer in clinical practice. 2004;2(4):161-73. 63. Anower EKMF, Matsumoto K, Habuchi H, Morita H, Yokochi T, Shimizu K, et al. Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application. Glycobiology. 2013;23(7):865-76. 64. Hecht JT, Hall CR, Snuggs M, Hayes E, Haynes R, Cole WG. Heparan sulfate abnormalities in exostosis growth plates. Bone. 2002;31(1):199-204. 65. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Archiv : European journal of physiology. 2007;454(3):345-59. 66. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285-95. 67. Stam F, van Guldener C, Becker A, Dekker JM, Heine RJ, Bouter LM, et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. Journal of the American Society of Nephrology : JASN. 2006;17(2):537-45. 68. Lee DH, Dane MJ, van den Berg BM, Boels MG, van Teeffelen JW, de Mutsert R, et al. Deeper penetration of erythrocytes into the endothelial glycocalyx is associated with impaired microvascular perfusion. PloS one. 2014;9(5):e96477. 69. Bovee JV, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiau AH, Bakker E, et al. EXTmutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. American journal of human genetics. 1999;65(3):689-98. 70. Reijnders CM, Waaijer CJ, Hamilton A, Buddingh EP, Dijkstra SP, Ham J, et al. No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas. Am J Pathol. 2010;177(4):1946-57. 71. Wiweger MI, de Andrea CE, Scheepstra KW, Zhao Z, Hogendoorn PC. Possible effects of EXT2 on mesenchymal differentiation--lessons from the zebrafish. Orphanet J Rare Dis. 2014;9:35. 72. Eickhoff MK, Winther SA, Hansen TW, Diaz LJ, Persson F, Rossing P, et al. Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. PloS one. 2020;15(12):e0243737. 73. Raghavan V, Rbaibi Y, Pastor-Soler NM, Carattino MD, Weisz OA. Shear stress-dependent regulation of apical endocytosis in renal proximal tubule cells mediated by primary cilia. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(23):8506-11.
RkJQdWJsaXNoZXIy MTk4NDMw